FDA to review Savara resubmitted Molbreevi BLA
Source: SeekingAlpha
2026-02-20 16:42:22 ET
More on Savara
- Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Savara resubmits MOLBREEVI BLA to FDA, seeks priority review
- Seeking Alpha’s Quant Rating on Savara
- Historical earnings data for Savara
- Financial information for Savara
Read the full article on Seeking Alpha
For further details see:
FDA to review Savara resubmitted Molbreevi BLA
Savara Inc.
NASDAQ: SVRA
SVRA Trading
7.46% G/L:
$5.81 Last:
435,634 Volume:
$5.50 Open:
SVRA Latest News
March 06, 2026 04:05:00 pm
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
SVRA Stock Data
$1,087,535,632
143,465,178
2.96%
33
N/A
Biotechnology & Life Sciences
Healthcare
US
Langhorne
